Mankind Pharma Limited (MANKIND) reported revenue of ₹4,031 Cr and net profit of ₹574 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
MANKIND fundamentals, Fundamental score 61/100
The statements below are read from Mankind Pharma Limited’s filed results, 13 filed quarters and 8 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Jul 31, 2026 · audited
Sales CAGR · 3Y+17.7%FY22 → FY25
Sales CAGR · 4Y+16.4%FY21 → FY25
PAT CAGR · 3Y+14.0%FY22 → FY25
PAT CAGR · 4Y+7.5%FY21 → FY25
Price · 1Y−9.4%EOD
Price CAGR · 3Y+9.5%EOD
Quarterly resultsConsolidated
₹ Cr
Jun2023
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
2,579
2,708
2,607
2,441
2,893
3,077
3,230
3,079
3,570
3,697
3,567
3,443
4,031
+12.9%
1,924
2,025
2,000
1,850
2,212
2,226
2,400
2,396
2,724
2,776
2,648
2,513
2,974
+9.2%
Operating profit
655
683
607
591
682
850
830
683
847
921
919
930
1,056
+24.7%
OPM %
25.4%
25.2%
23.3%
24.2%
23.6%
27.6%
25.7%
22.2%
23.7%
24.9%
25.8%
27.0%
26.2%
+2.5 pp
Other income
58.6
60.0
70.1
92.1
101
109
77.3
251
79.9
91.9
72.8
114
45.0
-43.7%
Interest
6.34
8.62
9.19
9.38
10.9
7.10
221
191
171
170
157
142
110
-35.6%
Depreciation
87.4
96.5
110
105
108
106
192
231
219
222
223
223
226
+3.2%
Profit before tax
620
638
558
569
664
847
494
513
537
622
506
656
766
+42.5%
Tax %
21.0%
20.4%
18.4%
16.7%
18.8%
22.5%
22.8%
16.8%
17.8%
16.7%
18.8%
15.2%
25.5%
+7.7 pp
Net profit
494
511
460
477
543
659
385
425
445
520
414
559
574
+29.1%
EPS (₹)
12.15
12.51
11.33
11.76
13.39
16.31
9.45
10.19
10.62
12.39
9.90
13.44
13.76
+29.6%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 13 quarters
RevenueNet profit
Revenue & net profit — Consolidated13 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±2.7%· EPS surprise: no estimates source· 1 earlier quarter has no dated filing on record
